These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 33941237)

  • 21. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are BiTEs the "missing link" in cancer therapy?
    Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
    Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
    Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
    Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent progress of bispecific antibody-based therapy for hematological malignancies].
    Ochi T
    Rinsho Ketsueki; 2022; 63(9):1298-1309. PubMed ID: 36198556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific antibodies in haematological malignancies.
    Viardot A; Bargou R
    Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
    Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
    Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
    Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application.
    Zhang C; Shi Y; Wu L; Wang C; Liao N; Wang F; Zhao B; Wang Y; Liu X
    ACS Synth Biol; 2022 Feb; 11(2):888-899. PubMed ID: 35113526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
    Nogami A; Sasaki K
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific antibodies for cancer therapy: A review.
    Krishnamurthy A; Jimeno A
    Pharmacol Ther; 2018 May; 185():122-134. PubMed ID: 29269044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Taking a BiTE out of the CAR T space race.
    Patel A; Oluwole O; Savani B; Dholaria B
    Br J Haematol; 2021 Dec; 195(5):689-697. PubMed ID: 34131894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific antibodies for immune cell retargeting against cancer.
    Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
    Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies.
    Ma L; Ma J; Sun X; Liu H
    Invest New Drugs; 2023 Jun; 41(3):522-531. PubMed ID: 37198354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
    Yu L; Wang J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bispecific Antibodies in the Treatment of Hematologic Malignancies.
    Duell J; Lammers PE; Djuretic I; Chunyk AG; Alekar S; Jacobs I; Gill S
    Clin Pharmacol Ther; 2019 Oct; 106(4):781-791. PubMed ID: 30770546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.